01 Nov, 2022 RNAi Roundtable: CNS Delivery and ALN-APP, an Investigational RNAi Therapeutic in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

On November 1, 2022, we hosted an online RNAi roundtable to review Alnylam’s CNS delivery platform and ALN-APP, an investigational RNAi therapeutic in development for Alzheimer’s Disease and cerebral amyloid angiopathy.

Access the replay
View the presentation

Eric Green
Senior Vice President, Development Programs

Kirk Brown, Ph.D.
Senior Director, Research, CNS Program

Tim Mooney
Director, Program Leader, ALN-APP Program